Showing 3521-3530 of 19350 results for "".
Dialogue with the Experts: Best Practices in NSCLC
https://reachmd.com/programs/project-oncology/dialogue-with-the-experts-best-practices-in-nsclc/9626/Lung Cancer is the leading cause of cancer death and the second most diagnosed cancer in both men and women in the US. Incidence rates vary from state to state, but are of concern in the South.1 These sobering statistics are compounded by the documented variations in non-small-cell lung cancer (NSCThe Diagnostic Challenges of Spinal Cord Lesions in MS
https://reachmd.com/programs/global-neurology-academy/diagnostic-challenges-spinal-cord-lesions-ms/9573/Dr. Jiwoh Oh reviews the importance of spinal cord MRI in multiple sclerosis diagnosis.Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingBeyond GDMT: Timely Consideration of Barostim in Heart Failure
https://reachmd.com/programs/cme/beyond-gdmt-timely-consideration-of-barostim-in-heart-failure/29820/Hear experts discuss best practices for identifying candidates for Barostim™ and the timing for adding a medical device to your patient’s treatment plan.Evaluating Biochemical Response in Primary Biliary Cholangitis
https://reachmd.com/programs/gi-insights/evaluating-biochemical-response-in-primary-biliary-cholangitis/54678/Primary biliary cholangitis (PBC) management relies on early initiation of ursodeoxycholic acid and ongoing assessment of biochemical response to guide care. Monitoring markers such as alkaline phosphatase, bilirubin, and liver stiffness helps identify patients at risk for disease progression and thRAS Across Tumors: Who to Test When
https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.New Pathways in the Treatment of DMD
https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, musclFreeze-All Policy: Is It Right for Everyone?
https://reachmd.com/programs/global-womens-health-academy/freeze-all-policy-it-right-everyone/9879/Dr. Roque discusses current papers and studies regarding the freeze-all policy and how to identify patients who will benefit from this technique.Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
https://reachmd.com/programs/cme/tbd/37671/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
https://reachmd.com/clinical-practice/cardiology/poly-hf-trial-a-polypill-strategy-for-heart-failure-with-reduced-ejection-fraction-hfref/48691/Review the POLY-HF trial results evaluating a once-daily polypill strategy to improve guideline-directed therapy and cardiac function in HFrEF.